Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
Micardis(R) - MicardisPlus(R) - Hypertonie (38 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 31: Hypertonie - Behandlung Abb. 32: Antihypertensiva - Nebenwirkung Abb. 33: Hypertonie - Behandlung Abb. 34: Antihypertensiva- Eigenschaften Abb. 35: Hypertonie - Behandlung - Richtlinien Aktuelles Bild - Abb. 36: Hypertonie - Behandlung - Zwingende Indikationen Abb. 37: Angiotensin-I-Rezeptorblocker - Einsatzbereich Abb. 38: Hypertonie - Zusammenfassung
Abbildung 36: Hypertonie - Behandlung - Zwingende Indikationen
Clinical trials have shown that some classes of antihypertensives can reduce the cardiovascular morbidity in patients with specific indications. The JNC 7 guidelines recommend the use of specific antihypertensive classes in such patient groups, based on such evidence.1 ARBs are recommended for patients with heart failure, diabetes and chronic kidney disease. Note that a lack of recommendation for a specific indication does not mean that the class has been shown to be non-beneficial. It may simply mean that large-scale trials have not yet been conducted. 1. Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560–2572.
 
Hypertonie - Behandlung - Zwingende Indikationen
Vorheriges Bild Nächstes Bild   


Abbildung 36: Hypertonie - Behandlung - Zwingende Indikationen
Clinical trials have shown that some classes of antihypertensives can reduce the cardiovascular morbidity in patients with specific indications. The JNC 7 guidelines recommend the use of specific antihypertensive classes in such patient groups, based on such evidence.1 ARBs are recommended for patients with heart failure, diabetes and chronic kidney disease. Note that a lack of recommendation for a specific indication does not mean that the class has been shown to be non-beneficial. It may simply mean that large-scale trials have not yet been conducted. 1. Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560–2572.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung